Resource Summary Report

Generated by RRID on Sep 8, 2026

HepG2-Red-FLuc

RRID:CVCL_5I98
Type: Cell Line

Proper Citation

RRID:CVCL_5I98

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5I98

Proper Citation: RRID:CVCL_5I98

Description: Cell line HepG2-Red-FLuc is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Hepatoblastoma

Comments: Population: Caucasian.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HepG2-Red-FLuc

Synonyms: Bioware Brite HepG2-Red-FLuc, IVISbrite HepG2 Red F-luc

Cross References: cancercelllines:CVCL_5I98, Revvity/PerkinElmer:BW134280, Wikidata:Q54882855

ID: CVCL_5I98

Hierarchy: cvcl_0027

Record Creation Time: 20220427T220335+0000

Record Last Update: 20260905T180251+0000

Ratings and Alerts

No rating or validation information has been found for HepG2-Red-FLuc.

No alerts have been found for HepG2-Red-FLuc.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Maus J, et al. (2026) Automatic Delineation of Tumor Spheroids in Microscopic Images Using Deep-Learning. ACS measurement science au, 6(2), 411.

Ljunggren H, et al. (2026) Drugs that act on both G protein-coupled receptors (GPCRs) and kinases: potentiation of effects, side effects and general aspects of drug pleiotropy. British journal of pharmacology, 183(13), 3471.

Fayn S, et al. (2025) Diagnosis and Treatment Response Monitoring of Liver Cancer Using Glypican-3-Targeted Single-Domain Antibody PET. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(24), 5237.

Labadie KP, et al. (2023) Glypican-3 targeted positron emission tomography detects sub-centimeter tumors in a xenograft model of hepatocellular carcinoma. EJNMMI research, 13(1), 35.

Labadie KP, et al. (2022) Glypican-3-Targeted 227Th ??-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular Carcinoma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 63(7), 1033.

Labadie KP, et al. (2021) Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma. Scientific reports, 11(1), 3731.